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Objective: The aim of this prospective observational study was to evaluate the efficiency of a new escalating
treatment strategy with vernakalant, flecainide and electrical cardioversion (EC) in patients with new onset atrial
fibrillation (AF) after cardiac surgery.
Material and methods: 24 patients with new onset AF after aortic valve surgery, coronary artery bypass surgery or
combined procedures were evaluated in this study. Additional including criteria were age between 18 and 80,
duration of AF less than four days, body weight less than 100 kg and no previous treatment with class I or III
antiarrhythmic drugs. Exclusion criteria were poor left ventricular ejection fraction (LVEF < 40%) and history of
myocardial infarction within 30 days. The patients were divided into converters and non-converters according to
their response to combination treatment with vernakalant and flecainide, and the groups were compared.
Results: The mean age of the population was 69.6 ± 6.3 years and 26.1% of patients were female. There were no
statistically significant differences between the two groups in terms of height, weight, gender distribution,
comorbidities, preoperative medication, left ventricular function and left atrium diameter. Interventricular septum (IVS) in
the non-converted group was significantly thicker compared to the converted group: 14.0 ± 1.00 vs. 10.40 ± 2.59 mm
(p = 0.036). While 14 patients (60.9%) were successfully converted into stable sinus rhythm by pharmacological treatment
with vernakalant and flecainide, 9 patients (39.1%, non-converted group) remained in AF. However, seven of them could
be converted after additional EC.
Conclusion: The combination of vernakalant and flecainide improves the conversion rate into a stable sinus rhythm in
postcardiotomy patients with new onset AF compared to single drug therapy. Furthermore it might be an excellent
precondition for successful EC in patients who are not converted after using both antiarrhtythmic drugs. Furthermore,
left ventricular hypertrophy might be a potential negative predictor of successful pharmacological cardioversion.
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Postoperative atrial fibrillation (AF) is the most common
complication after cardiac surgery, which occurs in up to
74% of patients who underwent on-pump and off-pump
procedures [1,2]. Furthermore, it may contribute to longer
hospital stays which can be associated with deterioration in
heart failure, prolonged inotropic support, use of intraaor-
tic balloon pump, and increased risk for cerebrovascular
accidents [3,4]. After more than a century of research, the
etiology and pathophysiology of this arrhythmia is still not
completely understood [2,5]. In terms of treatment, there
are several drugs, such as digitalis, Beta-blockers, calcium
channel-blockers, and pharmacological or electrical cardio-
version (EC), which were shown as efficient treatment strat-
egies of AF in patients undergoing cardiac surgery [6]. The
choice of treatment in each individual case depends on a
number of factors, such as age, comorbidities and clinical
status of patients with AF. Also, duration and etiology of
AF play a major role in the treatment choice [7].
If not approached within a short period of time, a de-
layed cardioversion may aggravate AF-associated symp-
toms and promote structural changes of the atria [8].
Therefore, it is of particular interest to achieve early car-
dioversion in patients with AF, especially when they suf-
fer from distressing symptoms or seriously compromised
cardiac function [1,3,9-11].
Vernakalant is an antiarrhythmic agent, which is used
for rapid cardioversion of recent onset atrial fibrillation. It
blocks early-activating K+ atrial channels and frequency-
dependent atrial Na+ channels, prolongs atrial refractory
periods and decreases atrial conduction without promoting
ventricular arrhythmia [12]. Flecainide is a class Ic antiar-
rhythmic agent, which can be used for the prevention of
ventricular and supraventricular arrhythmias [13]. Electrical
cardioversion delivers a direct current synchronization with
the R wave. It is usually done using external, transcutane-
ous electrode patches or internal cardiac electrodes [14].
All these treatment strategies have been shown as valuable
options in case of postcardiotomy AF [12-14], however so
far there has been no evidence regarding efficacy of step-
wise escalating therapy using vernacalant, flecainide and EC
after cardiac surgery.
In this study, we created a new cardioversion protocol
and assessed its cardioversion efficacy in postoperative pa-
tients with recent new onset AF.
Methods
Patients
Between December 2011 and September 2012, 24 patients
with new onset AF who underwent isolated or combined
aortic valve replacement and/or coronary artery bypass
surgery performed at our institution were evaluated in this
observational prospective study. Inclusion criteria were: age
between 18 and 80, duration of new onset AF less than4 days, body weight less than 100 kg and no previous
treatment with class I or III antiarrhythmic drugs. Pre-
operative exclusion criteria were: poor left ventricular
ejection fraction (LVEF < 40%), NYHA class III-IV, history
of myocardial infarction within 30 days before surgery,
long QT syndrome (uncorrected QT interval > 440 ms),
sick sinus node syndrome, higher degree atrio-ventricular
block (II°, III°) as well as bradyarrhythmia absoluta. Re-do
cardiac surgery patients were also excluded from this
observation.
Ethical clearance for this observational prospective study
was given by the institutional ethics committee of Cologne
University. Therefore, according to the Ethics Committee a
signed informed consent was not mandatory as both anti-
arrhythmic drugs used were approved in the ESC Guide-
lines and the risks are similar to the current standard
therapy [15].
Study protocol
Patients with new onset AF after a cardiac surgical pro-
cedure underwent treatment according to the protocol
shown in Figure 1. In all patients who were not effectively
anticoagulated for more than 48 hours after new onset AF,
an elective pre-interventional trans-esophageal echocardi-
ography was performed in order to exclude intracardiac
thrombus formations before pharmacological and/or elec-
trical cardioversion were commenced. Before the first ver-
nakalant administration, electrolyte levels (magnesium,
potassium) were checked and optimized, if indicated.
Electric cardioversion under sedation with weight ad-
justed etomidate was only performed in case of persist-
ent AF after sequential pharmacological treatment with
both vernakalant and flecainide. A successful cardioversion
was defined as a conversion into a stable sinus rhythm
within the time periods described in Figure 1.
Furthermore, according to the study protocol, all patients
were divided in two groups: patients who successfully con-
verted into a stable SR (converted group) and patients who
were not converted into a SR (non-converted group) after
single treatment with vernakalant or combination vernaka-
lant/flecainide before EC. Both groups were compared re-
garding patients baseline preoperative, intraoperative and
postoperative characteristics, past medical history, labora-
tory and echocardiographic parameters before treatment
with the view to elaborating possible predictors of non-
responders to pharmacological treatment.
Statistical analysis
All data were analyzed using Statistical Package for So-
cial Sciences, version 21.0 (SPSS Inc., Chicago, Illinois)
and are expressed as the mean ± standard deviation (SD)
in cases of normal distributed or median (interquartile
range) in cases of non-normal distributed continuous vari-
ables. Variables were tested for normal distribution using
Figure 1 Flowchart of studyprotcol which begins with the admission to ICU with bloodpressure-, oxygen saturation measurement and
blood sample collection and ends with EC.
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test and the Mann–Whitney U test were applied for com-
parison of continuous variables in case of normal or non-
normal distribution, respectively. Chi-square and Fisher
exact test were used for comparison of dichotomous vari-
ables. A p-value < 0.05 was considered to indicate statis-
tical significance.
Results
Tables 1, 2 and 3 represent basic demographic data, pa-
tient comorbidities, medical history, echocardiographic
parameters and general clinical characteristics of all pa-
tients included in this study.
The mean age of the population was 69.6 ± 6.3 years and
26.1% of patients were female. 14 patients (60.9%) were
successfully converted into a stable sinus rhythm after
treatment with vernakalant or combination vernakalant/
flecainide. A stable sinus rhythm could be restored in 12
patients (52.2%) after isolated treatment with vernaka-
lant, and in 2 further patients (cumulative 60.9%) after
additional dose of flecainide. One patient refused to
proceed with pharmacological treatment after the first dose
of vernakalant. Another patient refused EC after not suc-
cessful drug combination treatment (Figure 2). In total, we
were able to achieve a stable SR in 21 patients (95.5%) after
treatment with both antiarrhythmic drugs and EC.
Comparing converters vs. non-converters after pharma-
cological treatment, there were no statistically significant
differences in terms of height, weight, gender distribu-
tion, comorbidities, preoperative medication, left ventricu-
lar function and left atrium diameter between both groups(Tables 1, 2 and 3). However, we found that the inter-
ventricular septum (IVS) in the non-converted group
was significantly thicker compared to the converted group:
14.0 ± 1.00 vs. 10.40 ± 2.59 mm (p = 0.036).
Discussion
In this study, we investigated for the first time, a gradu-
ated scheme therapy of postcardiotomy AF with verna-
kalant, flecainide and EC. Notably, previous research on
AF after cardiac surgery was limited to the use of single
therapy with either vernakalant, other antiarrhythmic
drugs or/and EC. By comparing converted vs. non-
converted patients before EC we found significant differ-
ence in the thickness of IVS, which therefore might be a
potential negative predictor of successful pharmaco-
logical cardioversion.
The negative effect of long term AF has been extensively
studied in the previous research [2,16,17]. The incidence
of AF in postcardiotomy patients may also depend on the
type of surgery. It occurs in 32 - 44% after coronary artery
bypass grafting (CABG), 35% after OPCAB, 42% after
mitral valve, 49%-74% after aortic valve surgery, and 62%
of CABG combined with valve surgery [2,18]. AF after
cardiac surgery is associated with longer ICU stay and
complications, such as low output syndrome, renal failure
and stroke [19-22]. There is also a substantial amount
of research, mentioned in the updated Guidelines, as-
sociating AF with an increased risk of heart failure and
high mortality [23]. These facts enhance the import-
ance of rapid cardioversion in order to avoid further
adverse events.
Table 1 Laboratory parameters
Preoperative laboratory parameters All Converted n = 14 Non-converted n = 9 p-value
aPTT (sec) 26 (24;28) 26.5 (24.8;28) 24 (24;34) 0.557
Creatinin (mg/dl) 0.91 (0.79;1.14) 0.905 (0.81;1.11) 1.0 (0.81;1.24) 0.557
CRP (mg/l) 3.2 (3;15.4) 3.2 (3;20.8) 3 (3;11.8) 0.877 0.877
CK (U/l) 75.5 (63.5;149.8) 77 (64.5;138) 76 (61;192.5) 0.781
CK-MB (U/l) 15 (15;21) 15 (11.5;17) 18 (12;25) 0.516
GOT (U/l) 26 (23;28.8) 25.5 (19.8;28.5) 27 (23;31) 0.557
GPT(U/l) 21 (15;24) 20 (14.5;28) 21 (16;23.5) 0.744
Hemoglobin (g/dl) 13.3 ± 2.1 13.3 ± 2.4 13.5 ± 1.9 0.831
Quick (%) 90.1 ± 20.5 89.6 ± 17.1 89.7 ± 26.8 0.992
Platelets (x1E9/l) 211.5 ± 70.6 207.9 ± 76.2 216.8 ± 69.5 0.780
Troponin-T (ug/l) 0.42 ± 0.82 0.26 ± 0.39 0.77 ± 1.33 0.492
Uric acid (mg/dl) 46.8 ± 17.1 49.6 ± 19.7 44 ± 12.6 0.460
WCC (x1E9/l) 8.5 ± 1.8 8.9 ± 1.6 8.2 ± 2 0.370
Postoperative but before cardioversion
Ca (mmol/l) 2.1 ± 0.15 2.11 ± 0.16 2.1 ± 0.15 0.729
Creatinin (mg/dl) 1.57 ± 0.97 1.35 ± 0.77 2.0 ± 1.15 0.113
CRP (mg/l) 126 ± 91.5 128.9 ± 99.5 122.7 ± 89.2 0.880
Erythrocytes (x1E12/l) 3.46 ± 0.34 3.5 ± 3.9 3.4 ± 0.2 0.291
Hematocrit (%) 31.21 ± 3.22 31.6 ± 3.5 31.1 ± 2.8 0.742
Hemoglobin (g/dl) 10.15 ± 1.0 10.3 ± 1.1 10.1 ± 0.88 0.741
HbA1c (%) 5.83 ± 0.87 5.8 ± 0.95 5.9 ± 0.77 0.924
MCH (pg) 29.4 ± 1.53 29.0 ± 1.4 29.9 ± 1.7 0.178
MCV (fl) 90.0 ± 4.04 88.9 ± 3.3 91.6 ± 4.9 0.127
Mg (mmol/l) 1.05 ± 0.28 1.11 ± 0.34 0.96 ± 0.19 0.267
NtproBNP (ng/l) 1576 (833;3573) 1463 (721;2772) 3102 (1087;11838) 0.185
Potassium (mmol/l) 4.70 ± 0.64 4.5 ± 0.49 4.9 ± 0.83 0.153
PTC (ug/l) 0.5 (0.2;0.88) 0.6 (0.2;0.75) 0.4 (0.23 ± 3.5) 0.645
Platelets (x1E9/l) 219.3 ± 82.2 214.1 ± 93.5 232.6 ± 68.7 0.616
Sodium (mmol/l) 140.4 ± 3.7 140.1 ± 3.4 141.2 ± 4.3 0.511
TSH (mU/l) 2.37 ± 3.97 2.9 ± 4.9 1.7 ± 1.9 0.501
WCC (x1E9/l) 12.25 ± 5.5 12.12 ± 4.9 12.9 ± 6.7 0.761
aPTT: activated partial thromboplastin time, CK: creatine kinase, CRP: c-reactive protein, GOT:glutamic oxaloacetic transaminase, GPT: glutamate pyruvate transaminase,
HbA1c: Glycated haemoglobin, MCH: mean corpuscular haemoglobin, MCV: mean corpuscular volume, NtproBNP: N-terminal prohormone of brain natriuretic peptide,
PTC: procalcitonin, TSH:thyroid-stimulating hormone, WCC: white cell counts.
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an important role in rhythm control in patients with AF
and can be administered both orally and intravenously.
Vernakalant is a new alternative intravenous atrial selective
antiarrhythmic drug developed for rapid conversion of AF
into sinus rhythm [24]. This is a sodium- and potassium-
channel blocking agent, which effects all phases (0 – IV)
of the atrial action potential (AP) and terminates AF by
increasing the atrial effective refractory period (AERP)
by blocking the potassium (IKur, IKACh, IKr and Ito) and
sodium currents (INa) in a concentration-, rate- and
voltage-dependent manner [25].The effect of vernakalant on the treatment of recent-
onset atrial fibrillation has been widely debated in the
previous research [7,26-29]. Also, the negative influence
of IVS on the conversion into a sinus rhythm has been
already indirectly mentioned in the literature. Furthermore,
recent studies reported that the incidence of postoperative
AF was higher in patients with aortic valve replacement
[2]. This is generally consistent with our results as patients
with hypertrophied myocardium and therefore hypertro-
phied IVS usually have severe aortic stenosis which was
treated with surgical aortic valve replacement in our study.
Therefore, taking into consideration results of previous
Table 2 Baseline characteristics, past medical history and preoperative medication
All Converted n = 14 Non-converted n = 9 p-value
Age 69.63 ± 6.34 68.21 ± 7.21 71.22 ± 4.58 0.279
CVA (%) 13 21.4 0 0.253
COPD (%) 13 14.3 11.1 1.000
Diabetis mellitus (%) 17.4 14.3 22.2 1.000
Female (%) 26.1 21.4 33.3 0.643
Height (cm) 172.71 ± 8.33 172.64 ± 8.28 172 ± 9 0.862
Hyperlipidemia (%) 43.5 42.9 44.4 1.000
Hypertension (%) 78.3 78.6 77.8 1.000
PAD (%) 8.7 7.1 11.1 1.000
Renal insufficiency or creatinin >1.1 (%) 8.7 7.1 11.1 1.000
Smoker (%) 21.7 28.6 11.1 0.611
Weight (kg) 80.56 ± 13.17 81.24 ± 14.26 79.33 ± 12.87 0.748
ACE-inhibitors(%) 36.4 23.1 55.6 0.187
Aspirin (%) 86.4 84.6 88.9 1.000
Beta-blockers (%) 72.7 69.2 77.8 1.000
Ca-antagonist (%) 36.4 30.8 44.4 0.662
Clopidogrel (%) 4.5 7.7 0 1.000
Cortison (%) 4.5 7.7 0 1.000
Diuretics (%) 31.8 38.5 22.2 0.648
Statin (%) 63.6 69.2 55.6 1.000
COPD: chronic obstructive pulmonary disease,CVA: cerebrovascular accident, PAD: peripheral arterial disease.
Table 3 Intraoperative, postoperative and echocardiography data
All Converted n = 14 Non-converted n= 9 p-value
Cardioplegia type 0.444
Buckberg (%) 40 46.3 28.6
Calafiore (%) 60 53.8 71.4
CPB time (min) 109.86 ± 51.3 122.15 ± 59.54 94.13 ± 33.01 0.240
Operation duration (min) 233.52 ± 88.41 242.92 ± 114.4 223.33 ± 38.58 0.628
Operation urgency 0.441
Emergent (%) 4.3 7.1 0.0
Urgent (%) 13 7.1 22.2
Elective (%) 82.6 85.7 77.8
Reperfusion time (min) 36.41 ± 22.08 38 ± 26.32 36.63 ± 14.11 0.894
Total ischemic time (min) 64.05 ± 33.66 71.46 ± 38.27 52.5 ± 25.13 0.230
Hospital stay (days) 16.29 ± 5.72 16.4 ± 6.29 15.67 ± 5.61 0.818
Intensive care unit stay (days) 4 (2.75;6.25) 4 (3;6) 4 (2;19.5) 0.972
IABP 5 0 14.3 0.350
Ventilation duration (in hours) 17.45 ± 8.44 18.94 ± 10.31 49.67 ± 13.32 0.256
Ejection fraction (%) 55.82 ± 9.68 58 ± 8.43 42.33 ± 5.51 0.779
Left atrium (mm) 43.22 ± 7.5 41 ± 6.56 42.33 ± 5.51 0.779
Mitral insufficiency (%) 20 25 0 1.000
Interventricular septum (mm) 11.5 ± 2.59 10.43 ± 2.3 14 ± 1 0.036
CPB: Cardiopulmonary bypass, IABP: Intra-aortic balloon pump.
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Figure 2 Flowchart of studydesign and success of antiarrhythmic drugs and EC.
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in the present observation, thickness of the IVS might play
a significant role in affecting the success of pharmaco-
logical conversion rate.
Analyzing data on pharmacological conversion rate in
postcardiotomy patients and patients who had not under-
gone cardiac surgery, we found out that application of both
vernakalant and flecainide as monotherapy was associated
with worse conversion rates in postcardiotomy patients.
Kowey et al. in his prospective randomized double-blind
trial reported on the success rate of conversion with verna-
kalant into a sinus rhythm in postcardiotomy patients
which was 47% compared to the success rate in non-
surgical patients of up to 55% [7,26]. While there were no
useful data regarding conversion rate of postcardiotomy
patients after flecainide treatment, the success rate to this
drug in non-cardiac surgery patients ranged between 50–
67.5% in the previous literature [30-33]. Not surprisingly,
our findings showed a conversion rate after vernakalant
monotherapy which was slightly higher however compar-
able to the study by Kowey et al. and resulted in 52.2% of
success. Furthermore, our study showed a significant im-
provement in the conversion rate into a stable sinus rhythm
to 60.9% after additional application of flecainide in patients
who did not convert after monotherapy with vernakalant.
In interpreting these findings, we assume that the combin-
ation of both antiarrhythmic drugs is more effective in con-
verting recent onset atrial fibrillation in carefully selectedgroups of patients with AF after cardiac surgery. This might
be also important in regards to the fact that a substantial
number of patients resist EC due to sedation and further
fears related to this more demanding procedure. Despite
that, our analysis revealed a 91.3% conversion rate into a
stable sinus rhythm after treatment with both antiarrhyth-
mics and EC. Taking into consideration the fact that two
patients who were not converted in a sinus rhythm after
vernakalant and flecainide administration, refused further
electric cardioversion attempt, the combined cardioversion
rate might have been even higher.
Several authors suggested that the use of flecainide in
patients with structural heart defects may contribute to a
pro-arrhythmogenic side effects [34,35]. These studies are
particularly focused on the risk of ventricular arrhythmia
in patients with previous coronary heart disease and myo-
cardial infarction or ischemic cardiomyopathy. Therefore,
we excluded patients with ischemic cardiomyopathy
and previous myocardial infarction from our observa-
tion, as mentioned before. Furthermore, vernakalant with
the most common side-effects being dysgeusia, sneezing,
paresthesia, nausea, and hypotension appeared to have
no side-effects even in combination with flecainide in our
study. Also, there were no drug-induced life-threatening
ventricular arrhythmias observed after combinational treat-
ment with vernakalant/flecainide. However, it might be re-
lated to the relatively low number of patients observed in
our investigation.
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Beta-blockers were also shown to be an effective treatment
in post cardiotomy patients [36]. Compared to a high con-
version rate and quick action of vernakalant shown in our
study and previous research, amiodaron treatment for
recent-onset AF only resulted in 5% conversion within the
first 90 min with similar results in post cardiotomy patients
[37]. However, well-designed trials evaluating amiodarone
and focused on postoperative medical cardioversion are
lacking. Also, treatment with this drug can lead to serious
complications such as non-cardiac toxicity including pul-
monary, hepatic, thyroid, and neurologic side-effects.
Moreover, its intravenous administration can be associated
with hypotension, bradycardia, and thrombophlebitis, and
this agent should be used with caution in patients with se-
vere pulmonary disease and low pulmonary resistance. In
contrast, vernakalant is the first marketed drug with rela-
tive atrial selectivity and low rate of adverse events re-
ported, indicating a higher safety profile. Beta-blockers are
also relatively safe in terms of adverse events, however they
are mainly used as the main agents for ventricular rate
control rather than for rhythm control [36].
The result of our study may be interpreted to indicate
that the oral application of 300 mg flecainide added to
intravenously administered vernakalant in patients who
did not convert into a sinus rhythm may not only increase
the cardioversion rate but also prevent pro-arrhytmogenity
and reduce side effects of vernakalant. Recent studies
showed that the oral application of a single flecainide dose
of 300 mg in patients with structural heart disease is safe
and effective in carefully selected patients [2,38].
Our study has several limitations. The main limitation is
its non-randomized design and analysis of limited number
of patients from a single institution. Furthermore, previous
usual therapy strategies with non-class III antiarrhythmics,
such as Beta-blockers, as well as electrolytes were not
quantified. Larger prospective randomized studies with
this aggressive therapy protocol are needed to confirm
our preliminary results.
Conclusion
Our results show that the sequential combinational treat-
ment with vernakalant, flecainide and EC is a recommend-
able and effective therapy strategy to convert rapidly new
onset AF in carefully selected patients after cardiac surgery.
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